In this review, the authors focus on NAFLD/NASH and its clinical, economical, and patient related burdens.Read More
This retrospective cross-sectional study was conducted among patients recruited from a large, community-based hospital system’s outpatient liver clinic from 2001 to 2020.Read More
Currently, there are no Food and Drug Administration (FDA)-approved or European Medicines Agency (EMA)-approved therapies for NASH and only lifestyles interventions are recommended for the treatment of NAFLD. Prof Zelber-Sagi (Haifa, Israel) reviews best practices for lifestyle interventions in patients with NAFLD. She warns us against ultra-processed foods and drinks, that are so common in the Western world. She also highlights the benefits of the Mediterranean diet and physical activity.Read More
This retrospective study by T. Mori et al. (Shanghai Jiao Tong University School of Medicine, China) aimed to investigate NAFLD frequency and identify factors associated with NAFLD presence at acute
The authors included stroke patients admitted from 2016 to 2019, within 24 h of onset. Among 1672 stroke patients, 39.5% had NAFLD. Independent NAFLD-presence factors were high BMI, low
AST/ALT ratio, high serum albumin level, high palmitic acid serum levels, and high dihomo-gamma-linolenic acid level.
Further studies are warranted to determine the effects of these factors on stroke onset or to precise prevention.
The authors included stroke patients admitted from 2016 to 2019, within 24 h of onset…
NAFLD and NASH are common conditions with a rising burden. As pointed out by F. Kanwal et al. (Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center, Houston,
USA), “yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single global guiding strategy for the management of
NAFLD and NASH.”
The American Gastroenterological Association, in collaboration with 7 professional associations, convened an international conference comprising 32 experts from the United States, Europe, Asia,
and Australia. The participants reviewed and discussed published literature on global burden, screening, risk stratification, diagnosis, and management of individuals with NAFLD and NASH.